For emerging biotech companies, the right partnerships are pivotal to growth. Dr. Tony Sasse, Founder & Managing Director of Snoretox, shares how his team identified investors and collaborators who believed in their mission and understood their market. Learn how strategic alignment is helping Snoretox progress toward licensing and manufacturing deals that will bring their innovation to market.
Tony Sasse
Managing Director
Snoretox Ltd
Before launching into development, Dr Erwin Blomsma took a research-first approach, surveying veterinarians, analysing clinic data, and identifying a major gap in canine cancer care. He shares how this market insight built investor conviction and informed a therapy ultimately creating a pathway to longer, healthier lives for dogs with bladder cancer.
Oncology
Canine
Market Research
Milestone: Validation
Erwin Blomsma, PhD
CEO and Co-Founder
Benno Therapeutics BV
Crystal Culhane Ph.D.
Principal
Fish & Richardson P.C.
Crystal Culhane, Ph.D., applies her extensive academic background in organic chemistry to help life sciences organization protect their products and innovations through U.S. and foreign patent prosecution, client counseling, due diligence, patentability and freedom to operate opinions, patent opinions, and post-grant proceedings.
Known as a responsive communicator with a strong depth of knowledge, Crystal works with clients ranging from universities to start-ups and growing companies to multinational organizations to prepare intellectual property strategies that suit their business goals.
In recent years, Crystal has worked with a number of pharmaceutical clients in high-impact patent prosecution. Her clients include a large pharmaceutical company for which she has helped develop and manage a portfolio of several hundred patent families and another which in 2021 received its first-ever FDA approval for a new drug that treats a rare liver disease.
Crystal earned her doctorate in chemistry at Johns Hopkins University, where her research focused on the design, synthesis, and evaluation of novel optical and radioactive small molecule prostate cancer imaging agents. She has significant experience in various scientific disciplines, including synthetic organic chemistry, radiochemistry, biology, radiobiology, and small animal imaging.
Networking
